Respiratory Syncytial Virus Strain A2-2-20F
Application
Strain of respiratory syncytial virus (RSV) for vaccine and therapeutic research and development.
Key Benefits
Higher early viral load.
Induces greater necrotic airway damage and neurophil infiltration.
Market Summary
RSV is a highly contagious and ubiquitous virus that causes respiratory tract infections in individuals of all ages,...
Published: 3/1/2024
Contributor(s): Martin Moore
|
Respiratory Syncytial Virus (RSV) A2 Expressing Firefly Luciferase
Application
Recombinant RSV strain expressing firefly luciferase and the F & G genes from clinical strain A2001/2-20 for research and development of vaccines.
Key Benefits
F & G proteins included in this strain show different behavior than those of the typical A2 strain proteins.
May be adapted in a variety of assays, enabling the identification...
Published: 7/28/2023
Contributor(s): Martin Moore, Christopher Stobart
|
Helper Plasmids for Rescue of Respiratory Syncytial Virus
ApplicationPlasmids rescuing recombinant syncytial virus for RSV research and vaccine development.Key BenefitsAllow expression and recombination in vero cells.Optimized for human codon bios to increase expression in mammalian cells.Market SummaryRespiratory syncytial virus (RSV) is the major cause of acute lower respiratory tract infections in infants...
Published: 7/28/2023
Contributor(s): Martin Moore
|
Plasmid for Respiratory Syncytial Virus (RSV) Vaccine Development & Research
Applications
Bacterial artificial chromosome (BAC) plasmid containing the antigenomic sequence A2-BAG-BAF derived from multiple strains of RSV.
Key Benefits
Viral DNA is contained in a BAC, allowing for efficient mutagenesis and recombineering of viral DNA.
BAC is stable and can be used for cloning in common bacteria types like E. coli.
Provides...
Published: 7/28/2023
Contributor(s): Martin Moore, Anne Hotard (Lopez-Ona)
|
Recombinant Respiratory Syncytial Virus (RSV) Firefly Luciferase Reporter Strain
Application
Modified recombinant syncytial virus (RSV) strain expressing a bioluminescent reporter protein for high throughput screening and vaccine development.
Key Benefits
Provides a new high throughput screening tool for RSV vaccine development and drug discovery.
Firefly luciferase based assays show better signal-to-noise than fluorescence-based...
Published: 7/28/2023
Contributor(s): Richard Plemper, Martin Moore
|
Broad Spectrum Vaccine to Human Rhinovirus Serotypes
Application
A vaccine that provides protection from a broad spectrum of human rhinovirus serotypes.
Key Benefits
Targets numerous, specific human rhinovirus (HRV) serotypes and provides broad neutralizing antibodies.
Engineered bacterial artificial chromosome (BAC) expression of HRV to reproducibly express specific serotypes.
BAC system allows...
Published: 1/25/2024
Contributor(s): Martin Moore, Minh Nguyen, Sujin Lee
|
Recombinant RSV Strains Expressing Renilla Luciferase and G & F Proteins
Application
Recombinant respiratory syncytial virus (RSV) strains expressing the G and F Proteins from RSV strains as well as renilla luciferase for use in drug and vaccine screening.
Key Benefits
Provides new and needed tool for screening potential RSV therapies, ensuring they are broadly effective against multiple, distinct strains of the virus....
Published: 7/28/2023
Contributor(s): Martin Moore, Jia Meng
|
Recombinant Respiratory Syncytial Viruses (RSVs) Expressing the G and F Proteins from Various Strains
ApplicationRecombinant RSV Strains Expressing the G and F Proteins from various geographically distributed RSV strains for use in drug and vaccine screeningKey BenefitsProvides new and needed tool for screening potential RSV therapies, ensuring they are broadly effective against multiple, geographically distinct strains of the virus Expresses the red...
Published: 7/28/2023
Contributor(s): Martin Moore, Anne Hotard (Lopez-Ona), Christina Rostad, Barney Graham, Syed Moin
|
Novel Vaccine Antigen Presentation Platforms
Application
Combined antigen-adjuvant virus-like particle (VLP) vaccine platform for enhanced immune response.
Key Benefits
Chimeric VLPs (cVLPs) contain both antigen and adjuvant, thereby enhancing both cellular and humoral responses.
cVLPs are safer than live replicating vectored vaccines because of their lack of infectivity.
The cVLP manufacturing...
Published: 7/28/2023
Contributor(s): Baozhong Wang, Fu Shi Quan, Martin Moore, Richard Compans, Alan Aderem, Ioanna Skountzou, Jadranka Bozja
|
Untagged RSV A2-line 19F Strain Generated from BAC-RSV Clone
ApplicationStrain of respiratory syncytial virus (RSV) for vaccine and therapeutic research and development.Key Benefits High titer RSV strain. Strain A2-line 19F recapitulates human RSV infection in mouse models making it useful for initial vaccine studies. Market SummaryRespiratory syncytial virus (RSV) is the leading cause of lower respiratory tract...
Published: 7/28/2023
Contributor(s): Martin Moore
|